Our second flagship journal of 2021 comprises a selection of articles highlighting key advances across a range of therapeutic disciplines including haematology, rheumatology, respiratory medicine, and more. Themes covered in this issue appeal to a broad range of healthcare professionals and include COVID-19, acute myeloid leukaemia, and Ehlers-Danlos Syndrome, among others.
EMJ 6.2 2021
Latest articlesAll articles
Oral Corticosteroids for Patients with Eosinophilic Diseases: An Expert Panel View on Use, Overuse, and Strategies to Reduce Use
Severe asthma (SA), chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic granulomatosis with polyangiitis (EGPA) are three conditions driven by IL-5 and eosinophilic inflammation. As these conditions have high use of healthcare services, as well as lifestyle and psychological burdens, well-tolerated treatment to achieve optimal control is key.
Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease
Setting the scene, Bakris defined CKD as a reduction in kidney function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2), alongside the presence of albuminuria (≥30 mg/day) as an indication of kidney damage.
Heated Tobacco Products and Chronic Obstructive Pulmonary Disease: A Narrative Review of Peer-Reviewed Publications
An estimated 65 million people worldwide have moderate or severe chronic obstructive pulmonary disease (COPD), an umbrella term used to describe a group of progressive lung diseases that obstruct airflow such as emphysema and chronic bronchitis. Smoking contributes to an estimated 90% of COPD cases, as the harmful chemicals produced during tobacco combustion damage the lungs and airways. Although smoking cessation is the only intervention shown to improve COPD prognosis in smokers, many patients who try to quit continue to smoke.